In China, Rare Dissent Over a Program to Save on Drug Costs
Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.
missouribusinessalert2d
Missouri Minute: Purdue Pharma reaches settlement; Bayer pushes bill related to Roundup lawsuits
The settlement with 15 states will resolve lawsuits alleging the drug OxyContin caused the opioid epidemic. ( Reuters) Bayer ...
ENDPOINTS NEWS3d
An­thos' de­tailed mid-stage da­ta back its an­ti­co­ag­u­lant, but can the drug suc­ceed where Bay­er's failed?
Anthos Therapeutics' abelacimab shows lower bleeding risk vs Xarelto in atrial fibrillation trial, with 62% reduction in ...
The Courier Online4d
Bayern Munich at a loss to explain Champions League struggles
Flying in the Bundesliga, Bayern Munich is stuttering in the Champions League. The Bavarian powerhouse lost 3-0 at Feyenoord ...
VietnamPlus4d
Vietnam seeks to transform pharmaceuticals into spearhead industry
The Ministry of Planning and Investment, the Ministry of Foreign Affairs, and FPT Corporation co-hosted a working breakfast ...
Johnson & Johnson posts Q4 beat as drug sales offset MedTech weakness
Johnson & Johnson (JNJ) traded flat after exceeding Street forecasts with its Q4 2024 results thanks mainly to its Innovative ...
Agtech firm with local production hub expands retail distribution
A California-based agtech firm with a big St. Louis-area production facility is expanding its retail distribution.
BioNxt Solutions Inc.: BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
VANCOUVER, BC / ACCESS Newswire / January 21, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery ...
Thailand Business News6d
India Remains a Magnet for Pharmaceutical Investments Despite Regulatory Challenges
Bayer's expanded therapies and strategic collaborations in India aim to drive pharmaceutical growth amidst regulatory challenges and pricing pressures.